SCHEMBL5240263

SCHEMBL5240263

CC(C)Oc1ncnc2c1nc(-c1ccccc1Cl)n2-c1ccc(Cl)cc1

nearest known ligand 0.60

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 20/20 0.60
KCNH2 Q12809 1/20 0.60
CNR2 P34972 13/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5239715 0.89 CNR1 (0.61) CNR1KCNH2CNR2
SCHEMBL16418419 0.83 CNR1 (0.69) CNR1KCNH2CNR2
SCHEMBL30944056 0.82 CNR1 (0.46) CNR1KCNH2CNR2
SCHEMBL5238025 0.81 CNR1 (0.69) CNR1KCNH2CNR2
SCHEMBL38658599 0.81 CNR1 (0.69) CNR1KCNH2CNR2
SCHEMBL15202848 0.79 CNR1 (0.67) CNR1KCNH2CNR2
SCHEMBL5238344 0.79 CNR1 (0.67) CNR1KCNH2CNR2
SCHEMBL15202845 0.79 CNR1 (0.64) CNR1KCNH2CNR2
SCHEMBL5233969 0.76 CNR1 (0.98) CNR1KCNH2CNR2
SCHEMBL16418418 0.75 CNR1 (1.00) CNR1KCNH2CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100478343-C Purine compound and use as cannabinoid receptor ligands PFIZER (US) 2009-04-15 CN disclosed
CN-100439369-C Purine compounds and their use as cannabinoid receptor ligands PFIZER (US) 2008-12-03 CN disclosed
EP-1558615-B8 PURINE COMPOUNDS AND USE THEREOF AS CANNABINOID RECEPTOR LIGANDS PFIZER PROD INC (US) 2007-10-10 EP disclosed
CN-1955181-A Purine compound and use as cannabinoid receptor ligands PFIZER (US) 2007-05-02 CN disclosed
CN-1955182-A Purine compound and use as cannabinoid receptor ligands PFIZER (US) 2007-05-02 CN disclosed
US-7129239-B2 Purine compounds and uses thereof PFIZER INC. (US) 2006-10-31 US disclosed
US-20060241120-A1 Cannabinoid Receptor Ligands and Uses Thereof PFIZER INC 2006-10-26 US disclosed
CN-1708499-A Purine compounds and their use as cannabinoid receptor ligands PFIZER (US) 2005-12-14 CN disclosed
EP-1558615-A1 PURINE COMPOUNDS AND USE THEREOF AS CANNABINOID RECEPTOR LIGANDS Pfizer Products Inc. (US) 2005-08-03 EP disclosed
US-20040092520-A1 Purine compounds and uses thereof PFIZER INC. 2004-05-13 US disclosed
WO-2004037823-A1 PURINE COMPOUNDS AND USES THEREOF AS CANNABINOID RECEPTOR LIGANDS PFIZER PRODUCTS INC. (US) 2004-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241120-A1 Cannabinoid Receptor Ligands and Uses Thereof CNR1, CNR2, GPR18 CNR1 1/4885KCNH2 2953/4885CNR2 2/4885
US-20040092520-A1 Purine compounds and uses thereof CNR1, CNR2, P2RY1 CNR1 1/4885KCNH2 3016/4885CNR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.